Grifols Stock News

The biopharma industry has high ambitions to improve therapies for patients across many disease categories, drawing on a wealth of technological advances that have been emerging and maturing in recent years. Even after the mass mobilization against COVID-19, it is

Grifols, S.A. (NASDAQ:GRFS)s share price gapped down before the market opened on Thursday . The stock had previously closed at $12.55, but opened at $12.10. Grifols shares last traded at $12.01, with a volume of 8,198 shares traded. A number of brokerages have issued reports on GRFS. Barclays cut Grifols from an overweight rating to []

To provide a precise market overview, this Immunoglobulin market report is divided into several distinct and important market segments and applications. Through this comprehensive Market research study in this Immunoglobulin market report, industries will learn about the vast opportunities available

The Corner Renta 4 | Grifols (GRF) and GIC have obtained the relevant regulatory authorisations to allow The Sovereign Wealth Fund of Singapore to go ahead with its investment to buy 23.8% of Biomat for 990 million dollars. Grifols will, of course, still maintain operating control of the company, as well as access to the recovered plasma in the over 300 plasma donation centres Biomat has in the United States. The funds

Transparency Market Research (TMR) has published a new report titled, Subcutaneous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027. According to the report, the global subcutaneous immunoglobulin market was valued at US$ 4.0 Mn in

MANU, GRFS, IMCC, and INTZ have been added to the Zacks Rank #5 (Strong Sell) List on September 22, 2021

Spanish pharmaceutical company Grifols SA said Friday that it has reached an agreement to acquire a majority stake in German peer Biotest AG.

Spain-based biotech Grifols SA ( GRFS , Financial) is trading low due to the effects of the pandemic on sales and revenue. The company is completely vertically integrated in the plasma business.

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Grifols outlines some promising new initiatives and financial targets at its latest Capital Markets Day. The most notable shift this time around was the R&D/innovation focus, which should boost the lo

Singapore's wealth fund GIC agreed to invest around 1 billion dollars in Biomat, a U.S.-based plasma collection company owned by Grifols, thus becoming a strategic investor in the Spanish pharmaceutic

BARCELONA, Spain, April 28, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contribu

According to the GuruFocus discounted cash flow calculator as of April 21, the following companies have a high margin of safety and have grown their margins over a 10-year period.

Grifols operates in the very attractive and lucrative plasma business.

BARCELONA, Spain, April 9, 2021 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United S